Patents Assigned to Medibeacon, LLC
-
Patent number: 9376399Abstract: The present invention relates to pyrazine derivatives such as those represented by Formulas I and II. X1 to X4 of Formulas I and II may be characterized as electron withdrawing groups, while Y1 to Y4 of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing organ (e.g., kidney) function.Type: GrantFiled: October 7, 2013Date of Patent: June 28, 2016Assignee: MediBeacon LLCInventors: Raghavan Rajagopalan, Richard B. Dorshow, William L. Neumann, Dennis A. Moore
-
Patent number: 9114160Abstract: The present invention relates to pyrazine derivatives such as those represented by Formulas I and II below. X1 to X4 of the compounds of Formulas I and II may be characterized as electron withdrawing groups. In contrast, Y1 to Y4 of the compounds of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing renal function. In particular, an effective amount of a pyrazine derivative of the invention may be administered into a body of a patient. The pyrazine derivative that is in the body may be exposed to visible and/or infrared light to cause spectral energy to emanate from the pyrazine derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient.Type: GrantFiled: March 24, 2014Date of Patent: August 25, 2015Assignee: MediBeacon, LLCInventors: Raghavan Rajagopalan, Richard B. Dorshow, William L. Neumann
-
Patent number: 9005581Abstract: Provided herein are compounds, preparations and formulations comprising pyrazine derivatives having multiple poly(ethylene glycol) containing substituents. Many of the compounds disclosed herein are excretable by the renal system of a subject or patient and are useful for visualizing the renal system of a subject or patient. Upon excitation by electromagnetic radiation, a number of the compounds disclosed herein exhibit luminescence and are externally detectable when present in the body fluid of a patient or subject. Also provided herein are methods for visualizing the renal system of a subject or patient.Type: GrantFiled: March 4, 2014Date of Patent: April 14, 2015Assignee: MediBeacon, LLCInventors: Amruta Poreddy, William L. Neumann
-
Patent number: 8778309Abstract: The present invention relates to pyrazine derivatives represented by Formula I. X1 and X2 of Formula I may be characterized as electron withdrawing groups, while Y1 and Y2 of Formula I may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing organ (e.g., kidney) function. In a particular example, an effective amount of a pyrazine derivative that is capable of being renally cleared may be administered into a patient's body. The pyrazine derivative may be capable of one or both absorbing and emanating spectral energy of at least about 400 nm (e.g., visible and/or infrared light). At least some of the derivative that is in the body may be exposed to spectral energy and, in turn, spectral energy may emanate from the derivative.Type: GrantFiled: December 22, 2005Date of Patent: July 15, 2014Assignee: MediBeacon LLCInventors: Raghavan Rajagopalan, Richard B. Dorshow, William L. Neumann, Dennis A. Moore
-
Patent number: 8722685Abstract: The present invention relates to pyrazine derivatives such as those represented by Formulas I and II below. X1 to X4 of the compounds of Formulas I and II may be characterized as electron withdrawing groups. In contrast, Y1 to Y4 of the compounds of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing renal function. In particular, an effective amount of a pyrazine derivative of the invention may be administered into a body of a patient. The pyrazine derivative that is in the body may be exposed to visible and/or infrared light to cause spectral energy to emanate from the pyrazine derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient.Type: GrantFiled: January 4, 2012Date of Patent: May 13, 2014Assignee: Medibeacon, LLCInventors: Raghavan Rajagopalan, Richard B. Dorshow, William L. Neumann
-
Patent number: 8703100Abstract: Provided herein are compounds, preparations and formulations comprising pyrazine derivatives having multiple poly(ethylene glycol) containing substituents. Many of the compounds disclosed herein are excretable by the renal system of a subject or patient and are useful for visualizing the renal system of a subject or patient. Upon excitation by electromagnetic radiation, a number of the compounds disclosed herein exhibit luminescence and are externally detectable when present in the body fluid of a patient or subject. Also provided herein are methods for visualizing the renal system of a subject or patient.Type: GrantFiled: December 17, 2009Date of Patent: April 22, 2014Assignee: Medibeacon, LLCInventors: Amruta Poreddy, William L. Neumann
-
Patent number: 8697033Abstract: In some embodiments, the invention provides modified pyrazine derivatives containing a central pyrazine ring with two secondary amine groups attached directly to the central pyrazine ring and two amino carbonyl groups attached directly to the central pyrazine ring. The secondary amine groups are terminated by alkyl groups containing from 1 to 6 carbons. The amino carbonyl groups can be terminated by a wide range of substituents including, but not limited to, alkyl and alkylene groups, polyether groups, including poly(ethylene glycol) groups, secondary and tertiary amine groups, polyhydroxylated alkyl groups, amino carbonyl groups, amino thioketone groups, and combinations thereof. In some embodiments, the invention provides modified pyrazine derivatives useful as optical agents in a wide variety of biomedical imaging procedures, including diagnostic and imaging procedures.Type: GrantFiled: December 17, 2009Date of Patent: April 15, 2014Assignee: Medibeacon, LLCInventors: Amruta Poreddy, William L. Neumann
-
Patent number: 8697871Abstract: The present invention discloses a number of photoactive compounds designed to bind and inhibit serine proteases. Compounds disclosed herein may be utilized in a number of appropriate medical diagnostic and/or therapeutic procedures such as the monitoring of hemostasis, imaging and/or treatment of vulnerable plaques, and/or tumor imaging and/or treatment.Type: GrantFiled: November 13, 2012Date of Patent: April 15, 2014Assignee: Medibeacon, LLCInventors: William L. Neumann, Richard B. Dorshow
-
Patent number: 8664392Abstract: Provided are compounds and compositions of general Formula IX: E1-L-Ar—X-PA, that may be utilized in bioconjugation procedures, where Ar is a chromophore and PA is a functional group capable of being attached to any bioactive molecule of interest. The present invention provides Formulas I-III that are capable of being attached to a bioactive vector for the selective delivery of said photoactive pyrazine derivatives to a desired biological target.Type: GrantFiled: January 6, 2012Date of Patent: March 4, 2014Assignee: MediBeacon, LLCInventors: Raghavan Rajagopalan, Richard B. Dorshow
-
Publication number: 20140039191Abstract: The present invention relates to pyrazine derivatives such as those represented by Formulas I and II. X1 to X4 of Formulas I and II may be characterized as electron withdrawing groups, while Y1 to Y4 of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing organ (e.g., kidney) function. In a particular example, an effective amount of a pyrazine derivative that is capable of being renally cleared may be administered into a patient's body. The pyrazine derivative may capable of one or both absorbing and emanating spectral energy of at least about 400 nm (e.g., visible and/or infrared light). At least some of the derivative that is in the body may be exposed to spectral energy and, in turn, spectral energy may emanate from the derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient.Type: ApplicationFiled: October 7, 2013Publication date: February 6, 2014Applicant: MediBeacon, LLCInventors: Raghavan Rajagopalan, Richard B. Dorshow, William L. Neumann, Dennis A. Moore
-
Patent number: 8313729Abstract: This invention is directed to the general method of transforming non-photoactive bioactive small molecule compounds of known structure and function into photoactive analogs of the small molecules which exhibit both photoactivity and the original biological targeting activity. The general method for the design of the photoactive analogs of the small molecules includes: (a) selecting a desired bioactive molecule; (b) identifying the region of the molecule that contains an aromatic or a heteroaromatic motif; and (c) either replacing said motif with a photoactive functional group of similar size, or modifying said motif to make it photoactive. Other aspects include photoactive analog compounds and photodiagnostic and phototherapeutic uses thereof.Type: GrantFiled: February 26, 2008Date of Patent: November 20, 2012Assignee: Medibeacon, LLCInventors: William L. Neumann, Raghavan Rajagopalan, Dennis A. Moore, Richard B. Dorshow